Results 31 to 40 of about 224,676 (168)

The change in the clinical presentation of Graves’ disease: a 30 years retrospective survey in an academic Brazilian tertiary center

Archives of Endocrinology and Metabolism, 2020
Objective Graves’ disease (GD) is the main cause of hyperthyroidism among adults. It is an autoimmune condition classically marked by the Merserburg Triad (goiter, thyrotoxicosis, and orbitopathy), but the change in presentation of GD over time has ...
Wanesa Pinto, João H. Romaldini, Nicolas Perini, Roberto B. Santos, Danilo Villagelin   +4 more
doaj   +1 more source

The role of pain in Graves' orbitopathy: Associations with clinical activity and quality of life

Acta Ophthalmologica, EarlyView.
Abstract Purpose Pain is included in the clinical activity score (CAS) as an indicator of inflammatory activity in Graves' orbitopathy (GO), yet its clinical relevance has not been systematically evaluated. We therefore investigated the relationship between pain, other inflammatory signs and quality of life (QoL), and assessed the effect of intravenous
Gijsbert J. Hötte, Willem A. Dik, Ronald O. B. de Keizer, Sodaba Khatab, Marco Medici, Maaike de Bie, P. Martin van Hagen, Dion Paridaens   +7 more
wiley   +1 more source

Isolated primary amyloidosis of the inferior rectus muscle mimicking Graves’ orbitopathy

Einstein (São Paulo)
The diagnosis of Graves’ orbitopathy is usually straightforward. However, orbital diseases that mimick some clinical signs of Graves’ orbitopathy may cause diagnostic confusion, particularly when associated to some form of thyroid dysfunction.
Mário Luiz Ribeiro Monteiro, Allan Christian Pieroni Gonçalves, Alanna Mara Pinheiro Sobreira Bezerra   +2 more
doaj   +1 more source

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy guidelines for the management of Graves' Orbitopathy

, 2016
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease.
Bartalena, Luigi, Eckstein, Anja, Kahaly, George J., Salvi, Mario, Marcocci, Claudio, On behalf of the European Group on Graves'' Orbitopathy (EUGOGO), Dayan, Colin Mark, Perros, Petros, European Group on Graves' Orbitopathy (EUGOGO), Baldeschi, Lelio, Boboridis, Kostas, Wiersinga, Wilmar M   +11 more
core   +1 more source

The relation between clinical response and quality of life improvement after treatment with intravenous methylprednisolone in Graves' orbitopathy

Acta Ophthalmologica, EarlyView.
Abstract Background Quality of life (QoL) is a key outcome in Graves' orbitopathy (GO), but prior studies have reported overall QoL changes without evaluating whether improvements occur specifically in patients who achieve objective clinical response.
Gijsbert J. Hötte, Willem A. Dik, Ronald O. B. de Keizer, Sodaba Khatab, M. Medici, Sigrid M. A. Swagemakers, Peter J. van der Spek, P. Martin van Hagen, Dion Paridaens   +8 more
wiley   +1 more source

Graves' orbitopathy treated with immunosuppressive therapy and orbital radiotherapy in a tertiary care endocrine centre: case series

Sri Lanka Journal of Diabetes Endocrinology and Metabolism, 2016
Graves’ Orbitopathy (GO) is a localized entity of Graves’ disease, which is a challenging disease to treat. We describe 6 cases of moderate to severe GO who presented to our endocrine centre, with a mean age of 48.6 years and equal gender distribution ...
D. C. Kottahachchi, W. K. M. G. Amarawardena, N. A. S. Ariyawansa, S. Siyambalapitiya, K. A. Perera   +4 more
doaj   +1 more source

Diagnostic Options in Graves' or Non‐Graves' Thyrotoxicosis: A Review for Clinical Practice

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Distinguishing Graves' disease (GD) from the other causes of thyrotoxicosis is essential for appropriate management. The clinical phenotype of GD has evolved over time and is currently more heterogenous and milder than in the past. Consequently, the differential diagnosis of thyrotoxicosis is often challenging.
Lorenzo Scappaticcio, Pierpaolo Trimboli, Paola Caruso, Chiara Porcellini, Daniela Forestiere, Maria Ida Maiorino, Katherine Esposito, Giuseppe Bellastella   +7 more
wiley   +1 more source

Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report

Thyroid Research
Background Rituximab, an anti-CD20 monoclonal antibody that depletes B-cells, is a potential second-line treatment for moderate-to-severe active Thyroid Eye Disease that is resistant to steroids.
Mirco Armenti, Sara Maioli, Chiara Riva, Nicola Currò, Giorgia Moschetti, Mario Salvi, Ilaria Muller   +6 more
doaj   +1 more source

Impact of Steroid Pulse Therapy on Early Treatment Response and Relapse in Type 1 Autoimmune Pancreatitis

JGH Open, Volume 10, Issue 7, July 2026.
ABSTRACT Aims Despite the recommendation of steroid therapy for type 1 autoimmune pancreatitis (AIP), the value of steroid pulse therapy remains unclear. This study aimed to assess the efficacy and safety of steroid pulse therapy in patients with AIP. Methods and Results Of 121 patients with type 1 AIP who were identified, 116 with adequate follow‐up ...
Akihisa Adachi, Itaru Naitoh, Michihiro Yoshida, Yasuki Hori, Akihisa Kato, Kenta Kachi, Tadashi Toyohara, Kayoko Oda, Yusuke Kito, Kenji Urakabe, Toshitaka Mori, Hiromi Kataoka   +11 more
wiley   +1 more source

The Value of Multidetector Computed Tomography of Orbits in Globe Protrusion in Comparison to Hertel Exophthalmometry

Acta Clinica Croatica, 2017
The use of multidetector computed tomography (MDCT) is an integral part of contemporary diagnostics of Graves‘ orbitopathy. Th e aim of this study was to assess proptosis measurement by MDCT and to compare it to the current standard, Hertel ...
Igor Đorić, Miloš Žarković, Zoran Radojičić, Nikola Repac, Aleksandar Janićijević, Krešimir Rotim, Goran Tasić, Lukas Rasulić   +7 more
doaj   +1 more source